Total pharma M&A deals for January 2019 worth $91.23bn were announced in the United States, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 1436.3% over the previous month and a rise of 1488.8% when compared with the last 12-month average of $5.74bn.
The United States held a 99.1% share of the global pharma M&A deal value that touched $92.08bn in January 2019.
In terms of deal activity, the United States recorded 28 deals during January 2019, marking an increase of 100% over the previous month and a rise of 47.4% over the 12-month average.
Pharma M&A deals for January 2019: Top deals
The top five pharma M&A deals accounted for 99.99% of the overall value in the sector globally during January 2019.
The combined value of the top five pharma M&A deals stood at $91.21bn, against the overall value of $91.23bn recorded for the month. The top announced pharma M&A deal tracked by GlobalData in January 2019 was Bristol-Myers Squibb ‘s $82.83bn acquisition of Celgene .
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
Verdict’s parent company GlobalData plc provides business information to 4,000 of the world’s largest companies.